Skip to content
Search

Latest Stories

German court rules in favour of a pharmacist who refused to sell 'morning after' pills

In a first of its kind verdict, a German court has ruled in favour of a pharmacist who refused to sell the ‘morning-after-pill’ citing conscience reasons.

The now-retired pharmacist, who owned and operated a pharmacy in Berlin, never stocked or sold the ‘morning-after-pill’ due to his deeply held beliefs.


The legal proceedings against the pharmacist were initiated by the Berlin Chamber of Pharmacists after he refused to sell the product in his pharmacy and took the matter to the court.

ADF International, a faith-based legal advocacy organisation that supported the pharmacist in this case, said the verdict upholds the pharmacist’s right to act in accordance with his conscience.

"Personal beliefs and conscience influence all areas of a person’s life and are not simply laid down in a professional setting. This pharmacist in Berlin faced legal proceedings for choosing to act in line with his conscience. The court recognized that he did not violate the law and should not be forced to act against his personal convictions,” said Felix Böllmann, Legal Counsel for ADF International.

The Pharmacists’ Chamber can still appeal against the decision on or before January 20, 2020.

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less